Multi-local and serial cross-sectional prevalence study on antibodies against SARS-CoV-2 (COVID-19) in Germany

Multi-local and serial cross-sectional prevalence study on antibodies against SARS-CoV-2 (COVID-19) in Germany - MuSPAD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022335

Enrollment

60000

Registered

2020-07-08

Start date

2020-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1 COVID-19 U07.2 Suspicion of COVID-19

Interventions

Group 1: Serological tests for antibodies against SARS-COV-2 over the course of one year

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Included in sample taken via registration offices, sufficient knowledge of German for informed consent

Exclusion criteria

Exclusion criteria: Refusal of informed consent or contraindication to venipuncture

Design outcomes

Primary

Measure	Time frame
The aim is to determine the proportion of people with SARS-CoV-2 antibodies among the participants in up to 10 counties at 2 points in time over the course of one year.	—

Secondary

Measure	Time frame
Determination of age-specific seropositivity, comparison of total and age-specific seropositivities of different counties with each other and over time; influence of self-reported confirmed SARS CoV-2 infections, self-reported respiratory symptoms since February 2020, self-reported adherence to measures and demographic and comorbidity factors on the outcome of antibody testing; Influence of self-reported respiratory illness severity, evidence of active infection since February 2020, demographic and comorbidity factors on quantitative antibody titers; In the longitudinal sub-survey: conversion and reconversion rate between the 1st and 2nd time points; influence of self-reported symptoms, detected infection, demographic and comorbidity factors on conversion and reconversion rates; Influence of self-reported symptoms and confirmed infection, demographic and comorbidity factors on quantitative antibody titre over time	—

Measure

Time frame

Determination of age-specific seropositivity, comparison of total and age-specific seropositivities of different counties with each other and over time; influence of self-reported confirmed SARS CoV-2 infections, self-reported respiratory symptoms since February 2020, self-reported adherence to measures and demographic and comorbidity factors on the outcome of antibody testing; Influence of self-reported respiratory illness severity, evidence of active infection since February 2020, demographic and comorbidity factors on quantitative antibody titers; In the longitudinal sub-survey: conversion and reconversion rate between the 1st and 2nd time points; influence of self-reported symptoms, detected infection, demographic and comorbidity factors on conversion and reconversion rates; Influence of self-reported symptoms and confirmed infection, demographic and comorbidity factors on quantitative antibody titre over time

—

Countries

Germany

Contacts

Public ContactDaniela Gornyk

Helmholtz-Zentrum für Infektionsforschung GmbH

muspad@helmholtz-hzi.de+4953161813160

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 20, 2026